VTP 27999

Drug Profile

VTP 27999

Alternative Names: VTP-27999

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vitae Pharmaceuticals
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypertension; Kidney disorders

Most Recent Events

  • 16 May 2016 Chemical information added
  • 07 Jan 2015 Discontinued - Phase-I for Kidney disorders in USA (PO)
  • 06 Jul 2011 Vitae Pharmaceuticals completes enrolment in a Phase-I clinical trial in Kidney disorders in USA (NCT01217736)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top